Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.40 |
| ▸ | F10 | P00742 | 2/20 | 0.37 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 2/20 | 0.35 |
| ▸ | CALCA | P06881 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15022864 | 0.89 | GPR119 (0.42) | GPR119F10BTK | |
| SCHEMBL2598526 | 0.89 | GPR119 (0.44) | GPR119F10SLC6A9 | |
| SCHEMBL2598524 | 0.89 | GPR119 (0.44) | GPR119F10SLC6A9 | |
| SCHEMBL2597114 | 0.85 | GPR119 (0.43) | GPR119 | |
| SCHEMBL15022674 | 0.84 | SLC6A9 (0.43) | GPR119SLC6A9BTKCYP3A4CYP2C9 | |
| SCHEMBL15022676 | 0.84 | SLC6A9 (0.43) | GPR119SLC6A9BTKCYP3A4CYP2C9 | |
| SCHEMBL15023088 | 0.82 | GPR119 (0.36) | GPR119F10SLC6A9BTKCYP3A4 | |
| SCHEMBL15023675 | 0.82 | SLC6A9 (0.41) | GPR119SLC6A9 | |
| SCHEMBL15023674 | 0.82 | SLC6A9 (0.41) | GPR119SLC6A9 | |
| SCHEMBL15023116 | 0.81 | GPR119 (0.54) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754226-B2 | Piperidinyl-substituted lactams as GPR119 modulators | ARRAY BIOPHARMA INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20130158009-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | ARRAY BIOPHARMA, INC. | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158009-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | GPR119, GPR139, GPR39 | GPR119 1/4885F10 3693/4885SLC6A9 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.